The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Phase II study of MGTA-145 in combination with plerixafor for HSC mobilization in patients with SCD
Akshay Sharma, MBBS, St. Jude Children’s Research Hospital, Memphis, TN, outlines the rationale and aims of a Phase II study investigating the efficacy of the hematopoietic stem cell mobilization agent MGTA-145 in combination with plerixafor in patients with sickle cell disease (SCD) undergoing autologous gene therapy (NCT05445128). Whilst G-CSF is a very effective stem cell mobilization agent, it cannot be used in patients with SCD due to toxicity. Plerixafor can be used as an alternative in this patient population, but it is not as potent as G-CSF. This trial is evaluating whether combining plerixafor for MGTA-145 can reduce the number of apheresis cycles required in these patients. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Spotlight Therapeutics: Consultancy; CRISPR Therapeutics: Other: Clinical Trial Site PI, Research Funding; Novartis: Other: Clinical Trial Site PI; Magenta Therapeutics: Other: Clinical Trial Site PI; Vindico Medical Education: Honoraria; Medexus Inc: Consultancy; Vertex Pharmaceuticals/CRISPR Therapeutics: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Other: Clinical Trial Site PI.
